The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pretreated patients with metastatic colorectal cancer.
Kazuhisa Yamaguchi
No relevant relationships to disclose
Hiroya Taniguchi
No relevant relationships to disclose
Azusa Komori
No relevant relationships to disclose
Yukiya Narita
No relevant relationships to disclose
Shiori Uegaki
No relevant relationships to disclose
Sohei Nitta
No relevant relationships to disclose
Motoo Nomura
No relevant relationships to disclose
Shigenori Kadowaki
No relevant relationships to disclose
Daisuke Takahari
No relevant relationships to disclose
Takashi Ura
No relevant relationships to disclose
Masashi Andoh
No relevant relationships to disclose
Kei Muro
No relevant relationships to disclose